Form 4: IDEAYA Biosciences Executive Acquires Shares & Options

IDEAYA Biosciences' SVP and General Counsel, Douglas B. Snyder, reported acquiring common stock through an ESPP and a significant stock option grant.

Summary

• Douglas B. Snyder, SVP, General Counsel of IDEAYA Biosciences, Inc. (IDYA), reported transactions involving the company's securities.
• Acquired 1,039 shares of Common Stock on May 30, 2025, at a price of $16.9065 per share, through the Issuer's Employee Stock Purchase Plan (ESPP).
• Acquired an additional 1,041 shares of Common Stock on November 28, 2025, at a price of $16.9065 per share, also through the ESPP.
• Following these transactions, Mr. Snyder beneficially owns 2,080 shares of Common Stock directly.
• Received a grant of 130,000 Stock Options (right to buy) on January 30, 2026, with an exercise price of $32.19 per share.
• The stock options have an expiration date of January 30, 2036.
• The options vest 25% on January 1, 2027 (the first anniversary of the January 1, 2026 Vesting Commencement Date), and then 1/48th of the total shares vest monthly thereafter, leading to 100% vesting on January 1, 2030 (the fourth anniversary of the Vesting Commencement Date).
• Mr. Snyder beneficially owns 130,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. Insider acquisition, even through an ESPP, and a significant stock option grant with a higher strike price, generally indicate management's confidence in the company's future prospects and align their interests with long-term shareholder value.

Positives

• The acquisition of common stock through the Employee Stock Purchase Plan (ESPP) demonstrates management's belief in the company's value at the purchase price.
• The grant of 130,000 stock options aligns management's long-term interests with those of shareholders, incentivizing future stock price appreciation.
• The exercise price of the stock options ($32.19) is significantly higher than the ESPP purchase price ($16.9065), suggesting a forward-looking positive outlook on the company's growth potential.

Future Outlook

The vesting schedule for the stock options, extending to January 2030, indicates a long-term incentive structure for the executive, aligning their financial interests with the company's sustained performance over several years.

Industry Context

StockSavvy.ai notes that executive stock option grants and Employee Stock Purchase Plans are standard compensation practices in the biotechnology industry, designed to attract and retain talent while aligning management incentives with shareholder value creation. The specific terms, including exercise price and vesting schedule, are typical for long-term executive compensation in growth-oriented sectors like biotech.

Comparison to Industry Standards

• The ESPP purchase price of $16.9065 is likely at a discount to the market price at the time of purchase, which is a common feature of such plans across industries, including biotech, to encourage employee ownership.
• The stock option exercise price of $32.19, being above the ESPP purchase price, is standard for new grants, reflecting the market price at or near the grant date and requiring future stock appreciation for the options to be 'in the money'.
• A four-year vesting schedule for stock options, with a one-year cliff and monthly vesting thereafter, is a widely adopted practice in the technology and biotechnology sectors, comparable to companies like Moderna or Regeneron, ensuring long-term commitment from key executives.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value through stock ownership and performance-based options.
• Employees: The ESPP participation highlights a benefit available to employees, fostering broader employee ownership.

Next Steps

• The stock options will begin vesting on January 1, 2027, with 25% of the shares vesting.
• Subsequent vesting will occur monthly at a rate of 1/48th of the total shares until fully vested on January 1, 2030.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation and insider buying through an ESPP. While insider ownership and option grants are generally positive signals, indicating management's confidence and alignment, a single Form 4 typically does not provide sufficient new information to warrant a change in a seasoned investor's fundamental 'buy' or 'sell' recommendation. It reinforces a 'hold' position for those already invested, as it suggests continued executive commitment.

Keywords

IDEAYA Biosciences, IDYA, Form 4, Insider Transaction, Stock Option, ESPP, Employee Stock Purchase Plan, Common Stock, Executive Compensation, Biotechnology